Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification ma… Read more
Jafron Biomedical Co Ltd (300529) - Net Assets
Latest net assets as of September 2025: CN¥3.43 Billion CNY
Based on the latest financial reports, Jafron Biomedical Co Ltd (300529) has net assets worth CN¥3.43 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.54 Billion) and total liabilities (CN¥2.11 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.43 Billion |
| % of Total Assets | 61.93% |
| Annual Growth Rate | 23.45% |
| 5-Year Change | 17.68% |
| 10-Year Change | 491.19% |
| Growth Volatility | 27.17 |
Jafron Biomedical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Jafron Biomedical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jafron Biomedical Co Ltd (2011–2024)
The table below shows the annual net assets of Jafron Biomedical Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.33 Billion | +5.77% |
| 2023-12-31 | CN¥3.15 Billion | -12.19% |
| 2022-12-31 | CN¥3.59 Billion | +6.11% |
| 2021-12-31 | CN¥3.38 Billion | +19.41% |
| 2020-12-31 | CN¥2.83 Billion | +30.55% |
| 2019-12-31 | CN¥2.17 Billion | +26.05% |
| 2018-12-31 | CN¥1.72 Billion | +23.75% |
| 2017-12-31 | CN¥1.39 Billion | +17.52% |
| 2016-12-31 | CN¥1.18 Billion | +109.92% |
| 2015-12-31 | CN¥564.06 Million | +24.68% |
| 2014-12-31 | CN¥452.42 Million | +19.02% |
| 2013-12-31 | CN¥380.12 Million | +30.70% |
| 2012-12-31 | CN¥290.84 Million | +34.92% |
| 2011-12-31 | CN¥215.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jafron Biomedical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3584.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.51 Billion | 75.42% |
| Common Stock | CN¥798.61 Million | 23.95% |
| Other Comprehensive Income | CN¥119.69 Million | 3.59% |
| Total Equity | CN¥3.33 Billion | 100.00% |
Jafron Biomedical Co Ltd Competitors by Market Cap
The table below lists competitors of Jafron Biomedical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VIZIO HLDG.CL.A DL-0001
F:7UF
|
$973.76 Million |
|
Vir Biotechnology Inc
NASDAQ:VIR
|
$973.78 Million |
|
TripAdvisor Inc
NASDAQ:TRIP
|
$974.07 Million |
|
Trigano S.A
OTCGREY:TGNOF
|
$975.07 Million |
|
Allied Properties Real Estate Investment Trust
PINK:APYRF
|
$973.59 Million |
|
PT VKTR Teknologi Mobilitas
JK:VKTR
|
$973.51 Million |
|
Pacific Basin Shipping Limited
PINK:PCFBF
|
$973.48 Million |
|
Nyfosa AB
LSE:0A0K
|
$973.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jafron Biomedical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,147,475,025 to 3,333,906,225, a change of 186,431,200 (5.9%).
- Net income of 820,195,434 contributed positively to equity growth.
- Dividend payments of 340,117,509 reduced retained earnings.
- Share repurchases of 371,275,316 reduced equity.
- Other comprehensive income decreased equity by 431,028,394.
- Other factors increased equity by 508,656,985.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥820.20 Million | +24.6% |
| Dividends Paid | CN¥340.12 Million | -10.2% |
| Share Repurchases | CN¥371.28 Million | -11.14% |
| Other Comprehensive Income | CN¥-431.03 Million | -12.93% |
| Other Changes | CN¥508.66 Million | +15.26% |
| Total Change | CN¥- | 5.92% |
Book Value vs Market Value Analysis
This analysis compares Jafron Biomedical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 62.27x to 4.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.31 | CN¥19.07 | x |
| 2012-12-31 | CN¥0.41 | CN¥19.07 | x |
| 2013-12-31 | CN¥0.54 | CN¥19.07 | x |
| 2014-12-31 | CN¥0.64 | CN¥19.07 | x |
| 2015-12-31 | CN¥0.80 | CN¥19.07 | x |
| 2016-12-31 | CN¥1.60 | CN¥19.07 | x |
| 2017-12-31 | CN¥1.78 | CN¥19.07 | x |
| 2018-12-31 | CN¥2.16 | CN¥19.07 | x |
| 2019-12-31 | CN¥2.71 | CN¥19.07 | x |
| 2020-12-31 | CN¥3.46 | CN¥19.07 | x |
| 2021-12-31 | CN¥4.18 | CN¥19.07 | x |
| 2022-12-31 | CN¥4.48 | CN¥19.07 | x |
| 2023-12-31 | CN¥3.97 | CN¥19.07 | x |
| 2024-12-31 | CN¥4.35 | CN¥19.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jafron Biomedical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.60%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.63%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.61x
- Recent ROE (24.60%) is below the historical average (27.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 35.15% | 38.86% | 0.79x | 1.14x | CN¥54.21 Million |
| 2012 | 34.39% | 39.91% | 0.73x | 1.17x | CN¥70.94 Million |
| 2013 | 33.35% | 41.76% | 0.66x | 1.21x | CN¥88.77 Million |
| 2014 | 35.38% | 43.15% | 0.69x | 1.19x | CN¥114.81 Million |
| 2015 | 35.54% | 39.39% | 0.74x | 1.22x | CN¥144.03 Million |
| 2016 | 17.07% | 37.18% | 0.42x | 1.10x | CN¥83.71 Million |
| 2017 | 20.45% | 39.58% | 0.42x | 1.22x | CN¥145.31 Million |
| 2018 | 23.67% | 39.55% | 0.50x | 1.21x | CN¥232.13 Million |
| 2019 | 26.64% | 39.87% | 0.57x | 1.16x | CN¥356.58 Million |
| 2020 | 31.18% | 44.87% | 0.61x | 1.15x | CN¥594.56 Million |
| 2021 | 35.63% | 44.73% | 0.56x | 1.43x | CN¥860.93 Million |
| 2022 | 24.89% | 35.70% | 0.46x | 1.51x | CN¥532.14 Million |
| 2023 | 13.87% | 22.71% | 0.35x | 1.76x | CN¥121.74 Million |
| 2024 | 24.60% | 30.63% | 0.50x | 1.61x | CN¥486.80 Million |
Industry Comparison
This section compares Jafron Biomedical Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jafron Biomedical Co Ltd (300529) | CN¥3.43 Billion | 35.15% | 0.61x | $973.63 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |